SpectraCure Valuation
Is 2OK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2OK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2OK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2OK's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2OK?
Key metric: As 2OK barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 2OK's PB Ratio? | |
|---|---|
| PB Ratio | 1.4x |
| Book | SEK 111.50m |
| Market Cap | SEK 160.07m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 433.5x |
| Enterprise Value/EBITDA | -6x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 2OK's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
GME Geratherm Medical | 0.9x | 89.5% | €21.0m |
AAQ1 aap Implantate | 1.6x | n/a | €22.4m |
AUG Audientes | 3.9x | n/a | €6.9m |
PUS PULSION Medical Systems | 6.5x | n/a | €134.4m |
2OK SpectraCure | 1.4x | n/a | €160.1m |
Price-To-Book vs Peers: 2OK is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (3x).
Price to Book Ratio vs Industry
How does 2OK's PB Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Book vs Industry: 2OK is good value based on its Price-To-Book Ratio (1.4x) compared to the European Medical Equipment industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is 2OK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2OK's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sensus Healthcare
US$143.9m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$8.25
7D
4.4%
1Y
263.8%
Shandong Weigao Group Medical Polymer
HK$20.2b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.9%
1Y
-37.7%
LNA Santé
€240.3m
Engages in the management and operation of health establishments.
2N3
€23.00
7D
1.5%
1Y
17.7%